TwinBeech Capital’s PTC Therapeutics PTCT Stock Holding History

TwinBeech Capital’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-127,193	Closed	-$6.48M	–	926
2025 Q1	$6.48M	Buy	+127,193	New	+$6.35M	0.12%	210
2024 Q3	–	Sell	-36,952	Closed	-$1.13M	–	844
2024 Q2	$1.13M	Buy	+36,952	New	+$1.2M	0.02%	394
2024 Q1	–	Sell	-67,679	Closed	-$1.87M	–	797
2023 Q4	$1.87M	Sell	67,679 -124,843	-65%	-$2.85M	0.03%	413
2023 Q3	$4.31M	Buy	192,522 +153,304	+391%	+$5.7M	0.08%	285
2023 Q2	$1.59M	Buy	+39,218	New	+$1.92M	0.03%	402
2021 Q4	–	Sell	-20,705	Closed	-$770K	–	764
2021 Q3	$770K	Buy	+20,705	New	+$850K	0.05%	364
2021 Q1	–	Sell	-6,092	Closed	-$372K	–	634
2020 Q4	$372K	Buy	+6,092	New	+$359K	0.06%	335
2020 Q2	–	Sell	-11,776	Closed	-$525K	–	474
2020 Q1	$525K	Buy	+11,776	New	+$593K	0.21%	148

Other funds holding PTCT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

TwinBeech Capital's PTCT Position: Q2 2025 in Review

TwinBeech Capital sold out of PTC Therapeutics (PTCT) in Q2 2025, closing a stake of 127,193 shares — an estimated $6.48M sold.

TwinBeech Capital first reported a position in PTCT in Q1 2020 and held it in 8 quarters. The position peaked at $6.48M in Q1 2025. 283 funds tracked by Wall St. Rank hold PTCT as of Q2 2025.

TwinBeech Capital reported no remaining PTC Therapeutics position as of Q2 2025 after selling out during the quarter.
TwinBeech Capital sold 127,193 PTC Therapeutics shares in Q2 2025, an estimated $6.48M.
TwinBeech Capital first reported a position in PTC Therapeutics in Q1 2020 and held it in 8 quarters.
TwinBeech Capital's PTC Therapeutics position peaked at $6.48M in Q1 2025.
283 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2025.

Based on TwinBeech Capital's 13F filing for Q2 2025, filed 14 Aug 2025.